From bypassing legacy EHR bottlenecks to navigating strict DPDP mandates and restructuring the economics of chronic care, Lupin Digital Health's CEO outlines a blueprint for a value-based healthcare ecosystem.
While tertiary and quaternary medical outcomes inside Indian operating theatres are globally benchmarked, the period immediately following a patient's discharge remains a significant, high-risk blind spot. In an exclusive conversation with FE Healthcare, Sidharth Srinivasan, CEO, Lupin Digital Health, maps out how the organisation is leveraging clinical accountability, custom software architectures and human-in-the-loop artificial intelligence to build India's first large-scale digital therapeutics ecosystem. From bypassing legacy Electronic Health Record (EHR) bottlenecks to navigating strict Digital Personal Data Protection (DPDP) mandates and restructuring the economics of chronic care, he outlines a blueprint for a value-based healthcare ecosystem. (Edited Excerpts)
Q. Consumer tech and wellness apps are flooding the market with health trackers. What regulatory certifications and clinical trial metrics protect your B2B market share from this encroachment?
The critical distinction is the boundary between lifestyle tracking and absolute clinical accountability. To shield our institutional ecosystem, we established clinical hygiene that general consumer tech cannot replicate. Lupin Digital Health is the creator of India's first Class C medical device licensed by the Central Drugs Standard Control Organisation, operating under strict ISO 13485 quality management frameworks. Our protocols align directly with the international guidelines of the American College of Cardiology and the European Society of Cardiology, which accord cardiac rehabilitation a Level 1A mandatory recommendation.
We validated this platform through India's largest digital therapeutics study, registered with the Clinical Trials Registry-India across 12 distinct medical institutions. The data is definitive: our platform achieved an 80% improvement in target lipid profiles and HbA1c values, alongside a 90% medication adherence rate at the six-month mark, compared to just 40% in standard care. Most critically, we demonstrated a 60% reduction in unexpected, high-cost hospital readmissions. When clinicians see peer-reviewed validation of this scale, they formally write our rehab program onto their prescription pads, creating an institutional barrier to entry that big tech cannot touch.
Q. Indian operating theatres deliver world-class care, yet post-discharge outcomes remain a blind spot. What specific operational gaps and statistical drops in adherence did you identify that justified your B2B model?
The macroeconomic and clinical data points illustrate this chasm clearly. In India, 50% of patients delay their first outpatient department visit, which clinically ought to occur within 14 days of discharge. Beyond the six-month mark, fewer than 40% of patients return for any formal follow-up checks at all. Medication adherence is equally alarming. Over 60% of patients stop complying with their full medication protocol within 90 days of a critical procedure, frequently driven by unverified advice from family or local chemists.
Our model steps into this gap through a B2B architecture where hospitals maintain 100% ownership over the primary patient interface. We run our specialised care pathways and real-time triage networks as a white-labeled service underneath the hospital's brand. By keeping the clinical data loop active post-discharge, we bridge a multi-month care vacuum that traditionally costs the healthcare ecosystem billions in avoidable deterioration.
Q. Legacy hospital software is notoriously fragmented. How do you bypass EHR integration bottlenecks while remaining compliant with India's DPDP Act?
The hospital software landscape in India is highly fragmented, with zero standard API uniformity. We completely bypass this integration bottleneck by digitising information at the point of discharge directly from the patient. Since 95% of Indian hospitals issue printed discharge summaries, we ingest these documents using automated optical character recognition tools. This text is then verified by an internal medical nerve center of MBBS doctors who transcribe and audit every entry to ensure 100% data fidelity.
To serve data back to hospital administrators, our architecture scales across three execution models depending on institutional tech maturity. Independent centers use our secure cloud dashboard directly. Mid-tier hospital chains leverage our secure APIs to pull data back into their systems. For large hospital networks requiring the highest echelon of data isolation under the Digital Personal Data Protection (DPDP) Act, we deploy an on-premises cloud infrastructure. We host our applications and databases inside the hospital's private servers, ensuring zero patient data flows out of its perimeter. This setup is managed by our 45-member engineering team utilising robust open-source foundations, securing full ISO 27001 and HIPAA compliance while cutting implementation timelines down to under 14 days.
Q. Expanding tech-driven rehab into Tier 2 and Tier 3 networks brings unique economic challenges. How are you adjusting your regional footprint and pricing structures?
Operationally, we have scaled beyond major tier-one metros into regional markets like Sholapur, Perinthalmanna, Gulbarga, Hisar and Meerut, mapping our presence to local partner networks. The commercial distinction in Tier 2 and Tier 3 locations is not a baseline lack of spending power, but rather the structural packaging of the entry-level price. The upfront ticket size must be highly accessible for the broader public to drive organic adoption.
Our primary user interface requires zero digital sophistication, operating via standard phone calls, video consultations, or interactive WhatsApp workflows. If a patient cannot type, they send a voice note, which our backend systems process. Our care teams manage interventions across 15 distinct regional languages to remove cultural friction. Our long-term commercial strategy is built around driving mass volume rather than chasing premium margins. Keeping our unit costs accessible builds regional trust, turning cardiac rehabilitation from a luxury service into an affordable standard of care across these tier markets.
Q. As your patient base grows exponentially, what specific automation metrics allow your AI infrastructure to prevent a linear spike in human staffing costs?
Our core operational thesis is to utilise artificial intelligence to liberate clinical teams from routine administrative workflows. For instance, we dynamically manage over 300 distinct clinical cohorts based on age, gender, comorbidities and cardiac pumping capacity. Manually sorting thousands of daily entries into these micro-categories would require massive headcount, but our automated algorithms handle this parsing instantaneously.
Daily, our platform ingests over 2,000 prescriptions and 3,000 laboratory reports via specialised Optical Character Recognition (OCR). If a patient's serum creatinine or kidney metrics cross defined thresholds, the system flags the anomaly, adjusts the exercise tolerance protocol and alerts the supervising doctor. Furthermore, where our dietitians previously spent 30 minutes drafting a custom nutrition chart after a call, our proprietary small language models, trained on a repository of over 30,000 historical clinical diets, generate the baseline model instantly. The dietitian merely reviews and refines it, reducing preparation time to just 10 minutes and tripling direct patient interaction capacity.
In high-frequency, low-complexity areas like daily weight monitoring for fluid retention, we deploy automated conversational voice bots. The bot executes the check-in, parses natural speech and flags anomalies for human backup. Finally, we record and transcribe 100% of clinical calls, running them through automated compliance models to instantly catch any errors, such as a care manager mistakenly advising three grams of salt instead of a strictly prescribed two-gram limit.
Q. Lupin Digital Health is a wholly owned subsidiary of Lupin Limited. Does this massive repository of longitudinal patient data provide an R&D advantage to your parent pharmaceutical company?
I want to be completely unequivocal on this point: the strategic data advantage flowing back to Lupin Limited is absolutely zero. There is zero data integration between the two entities. In the digital health economy, there is a common aphorism that if you are not paying for the product, you are the product. We operate on a transparent, upfront service-fee model where patients and institutional partners pay for defined clinical services. We have zero commercial incentive to misappropriate or share asset data.
The operational reality of Indian healthcare economics demands absolute trust. Our partner hospitals and doctors view themselves as the strict custodians of their patients' medical records. If there were even a slight perception of an ulterior pharmaceutical marketing or R&D motive, our B2B partnerships would disintegrate overnight. We only access strictly anonymised, aggregated datasets, with the explicit consent of the host hospital, solely to refine our internal machine learning risk-stratification engines. Furthermore, Indian regulatory frameworks strictly prohibit pharmaceutical manufacturing corporations from directly interacting with or managing individual patient medical data. We maintain an absolute firewall at the infrastructural, technological and legal levels to preserve institutional trust.
Q. Through your Vitalyfe system, how close are you to predictive health, and is the Indian insurance market operationally ready to shift from fee-for-service to value-based healthcare contracts?
True clinical prediction with a 95% confidence interval requires millions of additional longitudinal data points, though Lupin Digital Health currently holds what is arguably the largest structured longitudinal cardiometabolic dataset in India, tracking weekly blood pressure, heart rates and quarterly lipids over extensive timelines. What we can execute right now with exceptional accuracy is risk stratification. Through Vitalyfe, we analyse corporate workforces or insurance books and divide them into high-risk, moderate-risk and low-risk tiers, enabling targeted fiscal spending.
For corporate employers, we convert static annual health checks into actionable analytics. For instance, we manage an 18,000-employee telecom corporation where we identified that 15% of their workforce carried high cardiac risks due to lifestyle factors or prior history. The employer unlocked our full cardiac rehab program specifically for that vulnerable tier, deployed a lighter preventive version for the moderate-risk segment and utilised general digital engagement for the remaining low-risk population, maximising their employee benefit returns.
Regarding insurance, the transition from traditional fee-for-service to value-based care is the definitive question for the next three to five years. The missing link has always been neutral, certifiably honest tracking of longitudinal medical outcomes. We are uniquely positioned to act as a neutral bridge because we manage over 30,000 insurance claims a month across major private insurers. We are currently running structured pilots where insurers provide financial incentives to hospitals that successfully prevent readmissions for chronic conditions within a six-month window. As these pilots demonstrate a measurable drop in corporate loss ratios, the commercial healthcare ecosystem in India will systematically pivot toward value-based outcomes.
This interview was first published in Financial Express Healthcare on July 8, 2026.
